MedTrace Logo

Erythropoietin and Iron Supplementation for Patients With Chemotherapy-induced Anaemia

NCT02731378 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 603

Last updated 2016-11-01

No results posted yet for this study

Summary

A multicentre, randomized, open-label, parallel-group, active controlled non-inferiority study

Conditions

  • Chemotherapy-induced Anaemia

Interventions

DRUG

Erythropoietins (EPO)

A routine dose 10,000 IU of EPO, three times weekly by subcutaneous injections.

DRUG

Aggressive iron dextran supplementation

Iron dextran 100 mg, BIW, through 90 minutes of IV infusion, for the first consecutive 5 weeks

DRUG

Erythropoietins (EPO)

Doubling EPO dosage to 20,000 IU, three times weekly by subcutaneous injections with a maximum of 5 doses

DRUG

Sustained iron dextran supplementation

Iron dextran 200 mg, Q3W, through 90 minutes of IV infusion and a maximum of 5 doses

Sponsors & Collaborators

  • Shanghai East Hospital

    lead OTHER

Principal Investigators

  • Yong Gao, PhD · Shanghai East Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2019-04-30
Completion
2019-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02731378 on ClinicalTrials.gov